Skip to Main Content


Skip Nav Destination
Issue Cover
Current Issue
Volume 13,
Issue 11
1 November 2023

About the Journal

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal

Noted This Week

AbbVie announced that it will buy ImmunoGen in a deal worth about $10.1 billion, acquiring ImmunoGen’s mirvetuximab soravtansine (Elahere), a first-in-class antibody–drug conjugate (ADC) approved for the treatment of platinum-resistant ovarian cancer. Mirvetuximab soravtansine binds to folate receptor alpha (FRα), delivering the microtubule-disrupting agent DM4 to cancer cells. ImmunoGen has other ADCs in its pipeline, including IMGN151, a next-generation anti-FRα ADC for ovarian cancer that could potentially treat other tumor types, and pivekimab sunirine, an anti-CD123 ADC targeting blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer.

More Noted This Week, November 17–30   »


Close Modal

or Create an Account

Close Modal
Close Modal